Targeting Kinase Signaling in Glioblastoma: Structural Optimization, Blood-Brain Barrier Dynamics and Combinatorial...

Area of Science:

• Neuro-oncology
• Medicinal Chemistry
• Pharmacology

Background:

• Small-molecule kinase inhibitors show promise for glioblastoma (GBM) but face limitations like poor blood-brain barrier (BBB) penetration and drug efflux.
• Clinical efficacy of these inhibitors is hindered by challenges in drug delivery and biological resistance mechanisms within the brain tumor microenvironment.

Purpose of the Study:

• To review current medicinal chemistry strategies and translational approaches for enhancing the efficacy of small-molecule kinase inhibitors in glioblastoma.
• To analyze factors contributing to clinical failures and propose future directions for overcoming therapeutic constraints in GBM treatment.

Main Methods:

• Literature analysis of medicinal chemistry modifications (macrocyclization, rigidification, bioisosteric capping) to improve BBB penetration and evade efflux transporters (P-glycoprotein, BCRP).
• Evaluation of carrier-mediated prodrug strategies targeting the LAT1 transporter.
• Review of clinical trial outcomes to understand limitations of monotherapies and the potential of combination strategies (e.g., with DNA damage repair inhibitors, immunotherapy, focused ultrasound).
• Assessment of preclinical models, advocating for patient-derived models over conventional cell lines.

Main Results:

• Direct structural optimization requires balancing multiple factors to reduce polarity and efflux.
• LAT1-targeting prodrugs offer a viable approach for potent compounds.
• Single-agent therapies often fail due to compensatory pathway activation and tumor heterogeneity.
• Combination therapies and multi-targeted agents demonstrate potential to prevent tumor adaptation.
• Improved preclinical models are crucial for better translation to clinical settings.

Conclusions:

• Overcoming glioblastoma therapeutic challenges necessitates advanced neuro-pharmacological design and a network oncology approach.
• Strategies include optimizing drug properties for BBB penetration, utilizing targeted delivery systems, and employing rational combination therapies.
• Bridging the translational gap requires more relevant preclinical models that mimic the disease's complexity.